Pietrantonio et al. pointed out that tumors with RET mutated genes (e.g., CCDC6-RET) tend to be unrecognized as tumors with a distinct molecular signature, although they constantly demonstrated a worse OS, reporting in particular a median OS 14.0 versus 38.0 months of the RET negative CRC patients (HR, 4.59; 95% CI, 3.64–32.66; p < 0.001) [17]. This evidence concerns the gene RET and colorectal carcinoma.